Cutaneous Reactions After SARS-CoV-2 Vaccination
abstract
This abstract is available on the publisher's site.
Access this abstract nowBACKGROUND
Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized.
OBJECTIVE
To describe and classify cutaneous reactions after SARS-CoV-2 vaccination.
METHODS
A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification.
RESULTS
From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment.
CONCLUSIONS
Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles:
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
Br J Dermatol 2021 Jul 13;[EPub Ahead of Print], A Català, C Muñoz-Santos, C Galván-Casas, M Roncero Riesco, D Revilla Nebreda, A Solá-Truyols, P Giavedoni, M Llamas-Velasco, C González-Cruz, X Cubiró, R Ruíz-Villaverde, S Gómez-Armayones, MP Gil Mateo, D Pesqué, O Marcantonio, D Fernández-Nieto, J Romaní, N Iglesias Pena, L Carnero Gonzalez, J Tercedor-Sanchez, G Carretero, T Masat-Ticó, P Rodríguez-Jiménez, AM Gimenez-Arnau, M Utrera-Busquets, E Vargas Laguna, AG Angulo Menéndez, E San Juan Lasser, M Iglesias-Sancho, L Alonso Naranjo, I Hiltun, E Cutillas Marco, I Polimon Olabarrieta, S Marinero Escobedo, X García-Navarro, MJ Calderón Gutiérrez, G Baeza-Hernández, L Bou Camps, T Toledo-Pastrana, A GuilabertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.